Popular diabetes drugs may ease dry eye, study suggests

NCT ID NCT07605572

Recruiting now Knowledge-focused Sponsor: Attikon Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether GLP-1 receptor agonists—drugs used for type 2 diabetes and obesity—can also improve dry eye disease. Researchers will measure changes in tear stability and eye surface health in 100 patients who have not taken these drugs before. The goal is to understand if these medications have an added benefit for the eyes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonists (a class of diabetes and obesity drugs)
What this could lead to: If this study shows a benefit, it could point toward a new way to treat dry eye in people with diabetes and obesity.
What could go wrong: This is an early observational study, not a controlled trial. It may find no effect, and results may not apply to everyone with dry eye.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORNEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal disorder diabetes mellitus dry eye syndrome obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORNEA DIABETE MELLITUS DIABETES TYPE 2 DRY EYE DISEASE (DED) GLP-1 OCULAR SURFACE

Contacts and locations

Locations

2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, GRC.
RECRUITING

Athens, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.